DTC
ATRA icon

Deep Track Capital’s Atara Biotherapeutics ATRA Stock Holding History

Deep Track Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,000
Closed -$11.8M – 56
2021
Q4 		$11.8M Buy
+30,000
New +$12.6M 0.83% 40

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Deep Track Capital's ATRA Position: Q1 2022 in Review

Deep Track Capital sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 30,000 shares — an estimated $11.8M sold.

Deep Track Capital first reported a position in ATRA in Q4 2021 and held it in 1 quarter. The position peaked at $11.8M in Q4 2021. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

  • Deep Track Capital reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Deep Track Capital sold 30,000 Atara Biotherapeutics shares in Q1 2022, an estimated $11.8M.
  • Deep Track Capital first reported a position in Atara Biotherapeutics in Q4 2021 and held it in 1 quarter.
  • Deep Track Capital's Atara Biotherapeutics position peaked at $11.8M in Q4 2021.
  • 144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Deep Track Capital's 13F filing for Q1 2022, filed 16 May 2022.